NIH Clinical Center: Search the Studies

Search the Studies

16 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.

Protocol Number	Title	Protocol Status	Min-Max Age	Institute	Keywords
21-C-0015	Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma	Participants currently recruited/enrolled	18-125 Years	NCI	Glioblastoma
20-C-0069	A First-In-Human Phase I Single-Agent Dose-Escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms	Participants currently recruited/enrolled	18-125 Years	NCI	Glioblastoma
20-C-0027	A Phase I Clinical Trial of Selinexor (KPT-330) in Combination with Temozolomide and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma	Participants currently recruited/enrolled	18-125 Years	NCI	Glioblastoma
19-C-0143	A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer	Participants currently recruited/enrolled	18-70 Years	NCI	Glioblastoma
19-C-0006	Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype	Participants currently recruited/enrolled	18-125 Years	NCI	Glioblastoma
18-N-0077	Cytokine Microdialysis For Real Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade	Completed Study; data analyses ongoing	18-125 Years	NINDS	Glioblastoma
18-C-0080	Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled Trial	Completed Study; data analyses ongoing	5-125 Years	NCI	Glioblastoma
17-C-0037	Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma	Participants currently recruited/enrolled	18-125 Years	NCI	Glioblastoma
17-C-0034	A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)	Completed Study; data analyses ongoing	18-125 Years	NCI	Glioblastoma
17-C-0009	Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and Glioblastoma	Completed Study; data analyses ongoing	18-125 Years	NCI	Glioblastoma
16-C-0081	A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent Glioblastoma	No longer recruiting/follow-up only	18-125 Years	NCI	Glioblastoma
16-C-0034	A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab	Completed Study; data analyses ongoing	18-125 Years	NCI	Glioblastoma
16-C-0011	A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas	Completed Study; data analyses ongoing	18-125 Years	NCI	Glioblastoma
15-C-0138	Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed Glioblastoma	Completed Study; data analyses ongoing	18-125 Years	NCI	Glioblastoma
10-C-0166	A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab	Participants currently recruited/enrolled	18-72 Years	NCI	Glioblastoma
04-C-0200	Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence	Participants currently recruited/enrolled	18-125 Years	NCI	Glioblastoma